Improving immunotherapy response after disease progression
Benjamin P. Levy, MD, associate professor at Johns Hopkins School of Medicine and clinical director of Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the need to transform “cold” tumors to “hot” tumors in order to improve immunotherapy response after non-small cell cancer progression.
Tissue, plasma testing needed to guide treatment decisions
Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute, stresses the importance of next-generation sequencing and plasma-based testing when planning patients’ treatment course.
Research focuses on fusing genomics, immuno-oncology revelations
Steven J. O’Day, MD, executive director of John Wayne Cancer Institute, discusses the complex interplay between genomics and immuno-oncology.
Role of immunotherapy after progression remains unclear
Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute, discusses recent treatment advances for non-small cell lung cancer and questions that remain for patients whose disease progresses after chemotherapy-immunotherapy.
Thank you for participating in this module. Click below to download the certificate.